MSNBC - Merck’s lack of growth comes from the charge associated with paying its monster $4.85 billion settlement for Vioxx. While it’s an awful lot of money to give up, these things happen, and investors should be willing to excuse them — assuming they …

Originally Syndicated via RSS from Live Search News: vioxx